

23 October 2019

Proposed Share Consolidation for MedAdvisor

MedAdvisor Limited (ASX: **MDR**, the **Company**), Australia's leading digital medication management company today announced it has recommended to shareholders that the Company undertakes a consolidation of the Company's issued capital on the basis of one (1) new share for every seven (7) shares currently on issue.

The Board believes the proposed consolidation is an important step towards achieving MedAdvisor's aim of expanding the business internationally. The recent capital raising has strengthened the Company's balance sheet enabling it to accelerate the business in the US, UK and Asian markets as well being better positioned to seek strategic opportunities to grow the business.

The Consolidation is proposed by the Company in order to better position the business internationally by increasing the share price via the share consolidation. A higher share price will make the Company more attractive to international investors as well as to potential customers. The Boards believes that having less shares on issue and therefore a higher share price better positions the business internationally.

A resolution to this effect will be put to shareholders at the Company's Annual General Meeting (AGM) on Mondy 18 November 2019. If shareholders approve the consolidation at the AGM, the issued capital in MedAdvisor will reduce from approximately 1.72 billion shares to approximately 196 million shares. As the consolidation applies equally to all the Company's security holders, individual holdings will be reduced in the same ratio. The value of individual holdings at the time of the consolidation will not change (subject only to the rounding of fractions).

The timetable for consolidation if shareholders approve Resolution 5, is as follows:

| Event | Date |
|---|-----------|
| AGM | 18-Nov-19 |
| Entity tells ASX that shareholders have approved consolidation | |
| Last day for trading in pre-consolidated securities | 19-Nov-19 |
| Trading in the reorganised securities on a deferred settlement basis starts | 20-Nov-19 |
| Last day for the entity to register transfers on a pre-consolidation basis | 21-Nov-19 |

| Event | Date |
|--|-----------|
| First day for entity to send notice to each shareholder First day for issue of new Holding Statements First day for Company to register Shares on a post-consolidation basis | 22-Nov-19 |
| Dispatch Date - deferred settlement market ends Last day for securities to be entered into the holder's security holdings and Last day for the entity to issue them and send the statements to the holder Last day for entity to send notice to each shareholder | 28-Nov-19 |
| Normal T+3 trading starts provided the entity tells ASX by noon the previous day that dispatch has occurred | 29-Nov-19 |
| Settlement of trades conducted of shares on a T+2 basis and the first settlement of on-market trades conducted on a deferred settlement basis occurs | 03-Dec-19 |

The above dates are indicative only and, subject to the Listing Rules, are subject to change without notice. Shareholders are encouraged to review the Explanatory Memorandum in the Notice of Meeting for the AGM, which was lodged with the ASX on 22 October 2019.

---ENDS---

For more information

Carlo Campiciano
Company Secretary
Tel: +61 3 9095 3036
corporate@medadvisor.com.au

Jennifer Duraisingam
Corporate Communications Manager
Tel: +61 3 9095 3036
jenniferd@medadvisor.com.au

About MedAdvisor

MedAdvisor is a world class medication management platform that empowers users to more simply manage their medication and improve adherence. MedAdvisor's highly automated and intuitive software system connects users to tools and education materials from their local/preferred pharmacy. In Australia, MedAdvisor has connected over one million users through ~55% of Australian pharmacies and a network of thousands of GPs. MedAdvisor has recently partnered with Adheris in the US, Zuellig Pharma in Asia and launched into the UK on track to become one of the largest players in the global digital adherence market. In 2018, was recognised in the AFR Fast 100.